Loading company…
Sudo Biosciences develops drugs for immune-mediated inflammatory conditions.
Sudo Biosciences develops TYK2 inhibitors for immune-mediated inflammatory conditions, including psoriasis, lupus, and other autoimmune disorders. Founded in California in 2020, the company has offices in Indianapolis and London. It raised USD 30 million in Series B funding in January 2024 from Dementia Discovery Fund, Leaps by Bayer, and UPMC.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in